Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis
Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis
复制标题
MiR-155 在血液系统恶性肿瘤中的预后和临床病理学意义：系统评价和荟萃分析
DOI：
10.7150/jca.28537
复制
发表时间：
2019-01
影响因子：
3.9
通讯作者：
Yu Hu
中科院分区：
文献类型：
--
作者：
Lu Tang;Yi-zhong Peng;Cheng-gong Li;Hui-wen Jiang;Heng Mei;Yu Hu
背景：据报道，多种类型的恶性血液病中都存在miR-155的异常表达。然而，miR-155的预后和临床病理价值仍不清楚。在此，我们进行了系统回顾和荟萃分析，以全面评估miR-155表达在血液系统恶性肿瘤中的预后和临床病理学意义。研究方法：我们系统检索了PubMed、EMBASE、ISI Web of Science、科克伦图书馆数据库和奥维德，以识别2008年1月1日至2018年8月1日期间发表的合格研究。使用合并的风险比（HR）和比值比（OR）以及相应的95%置信区间（CI）来检测miR-155在血液恶性肿瘤中的预后和临床病理学作用。结果如下：本荟萃分析共纳入了18项研究，包括2316例患者，表明2114例患者中miR-155表达升高与总生存期（OS）较差之间存在显著相关性（合并HR = 1.72，95%CI [1.50-1.97]，p<0.001）。miR-155表达水平升高与较短的无事件生存期相关（EFS，汇总HR = 1.55，95%CI [0.94-2.57]，P=0.002），无病生存期（DFS，合并HR = 1.38，95%CI [1.13-1.68]，P=0.001），无进展生存期（PFS，合并HR = 1.58，95%CI [1.06-2.35]，p<0.001）和无治疗生存期（TFS，合并HR = 1.67，95%CI [1.16-2.39]，P=0.006）。此外，发现miR-155的过表达与FLT 3/ITD的存在显著相关。（OR=4.751，95%CI [3.229-6.990]，P<0.001），WT 1突变多552例AML患者中CEBPA基因突变发生率（OR=2.090，95%CI [1.240-3.522]，P=0.006）较低（OR=0.477，95%CI [0.286-0.794]，P=0.004）。结论：MiR-155表达与多种白血病相关表型及恶性血液病预后不良有关。因此，miR-155过表达可能是一个令人信服的不利预后指标，有助于临床决策过程。
Background: Aberrant miR-155 expression has been reported in various types of hematologic malignancies. However, the prognostic and clinicopathological value of miR-155 remains unclear. Here, we performed this systemic review and meta-analysis to comprehensively evaluate the prognostic and clinicopathological significance of miR-155 expression in hematologic malignancies. Methods: We systematically searched the PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2008 to Aug 1, 2018. The pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic and clinicopathological role of miR-155 in hematologic malignancies. Results: A total of 18 studies including 2316 patients were enrolled in the present meta-analysis, indicating significant association between elevated miR-155 expression and poor overall survival (OS) in 2114 patients (pooled HR = 1.72, 95%CI [1.50-1.97], p<0.001). Elevated miR-155 expression level was related to shorter event free survival (EFS, pooled HR = 1.55, 95%CI [0.94-2.57], P=0.002), disease free survival (DFS, pooled HR = 1.38, 95%CI [1.13-1.68], P=0.001), progress free survival (PFS, pooled HR = 1.58, 95%CI [1.06-2.35], p<0.001) and treatment free survival (TFS, pooled HR = 1.67, 95%CI [1.16-2.39], P=0.006). Additionally, overexpression of miR-155 was found to be significantly related to FLT3/ITD presence (OR=4.751, 95%CI [3.229-6.990], P<0.001), more WT1 mutation (OR=2.090, 95%CI [1.240-3.522], P=0.006) and less CEBPA mutation (OR=0.477, 95%CI [0.286-0.794], P=0.004) in 552 AML patients. Conclusion: MiR-155 expression was found to be associated with several leukemia-related phenotype and poor prognosis in hematologic malignancies. Therefore, miR-155 overexpression might be a convinced unfavorable prognostic indicator that helps the clinical decision-making process.
登录
查看更多内容
影响因子：
20.3
作者：
Linda M. Scott;Curt I. Civin;P. Rørth;A. Friedman
通讯作者：
Linda M. Scott;Curt I. Civin;P. Rørth;A. Friedman
影响因子：
10.1
作者：
Papaioannou D;Nicolet D;Volinia S;Mrózek K;Yan P;Bundschuh R;Carroll AJ;Kohlschmidt J;Blum W;Powell BL;Uy GL;Kolitz JE;Wang ES;Eisfeld AK;Orwick SJ;Lucas DM;Caligiuri MA;Stone RM;Byrd JC;Garzon R;Bloomfield CD
通讯作者：
Bloomfield CD
影响因子：
--
作者：
Papageorgiou SG;Kontos CK;Diamantopoulos MA;Bouchla A;Glezou E;Bazani E;Pappa V;Scorilas A
通讯作者：
Scorilas A
影响因子：
2.9
作者：
Wu X;Wang F;Li Y;Wang X;Liu P;Zhang H;Ge Z;Zhang X;Gao C;Chen B
通讯作者：
Chen B
影响因子：
28.5
作者：
Faraoni I;Laterza S;Ardiri D;Ciardi C;Fazi F;Lo-Coco F
通讯作者：
Lo-Coco F